Publications by authors named "Isabelle Desmoulins"

Claim this Profile
S
Small Extracellular Vesicles as Biomarkers in Sarcoma Follow-Up: Protocol for a Prospective, Multicentric Pilot Study.
Valentin Vautrot, Alice Hervieu, Aurélie Bertaut, Céline Charon-Barra, Isen Naiken, Isabelle Desmoulins

JMIR Res Protoc· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib.
Sylvain Ladoire, Ariane Mamguem Kamga, Loick Galland, Manon Reda, Isabelle Desmoulins

NPJ Breast Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world prevalence, treatment and survival of "high risk" early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registry.
Sylvain Ladoire, Ariane Mamguem Kamga, Loick Galland, Isabelle Desmoulins, Didier Mayeur

Breast· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Respective contribution of baseline clinical data, tumour metabolism and tumour blood-flow in predicting pCR after neoadjuvant chemotherapy in HER2 and Triple Negative breast cancer.
Neree Payan, Benoit Presles, Charles Coutant, Isabelle Desmoulins, Sylvain Ladoire

EJNMMI Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
Nicolas Roussot, Guillaume Constantin, Isabelle Desmoulins, Anthony Bergeron, Laurent Arnould

Eur J Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Live birth rates after breast cancer among women who desired a child].
Pauline Charpentier, Mathilde Cavalieri, Isabelle Desmoulins, Charles Coutant

Bull Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
Thierry Petit, Nawale Hajjaji, Eric-Charles Antoine, Marc-Antoine Benderra, Michel Gozy, Isabelle Desmoulins

Cancer Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2-Low Luminal Breast Carcinoma Is Not a Homogenous Clinicopathological and Molecular Entity.
Céline André, Aurélie Bertaut, Sylvain Ladoire, Isabelle Desmoulins, Clémentine Jankowski

Cancers (Basel)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.
Angéline Galvin, Coralie Courtinard, Fanny Bouteiller, Sophie Gourgou, Florence Dalenc, Isabelle Desmoulins

Eur J Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carboplatin and Etoposide for the Treatment of Metastatic Prostate Cancer with or without Neuroendocrine Features: A French Single-Center Experience.
Jérémy Baude, Julie Niogret, Pierre Jacob, Florian Bardet, Isabelle Desmoulins

Cancers (Basel)· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy.
Silvia Mihaela Ilie, Nathalie Briot, Guillaume Constatin, Alis Ilie, Francoise Beltjens, Isabelle Desmoulins

Front Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.
Fanny Le Du, Matthieu Carton, Thomas Bachelot, Mahasti Saghatchian, Barbara Pistilli, Isabelle Desmoulins

Oncologist· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Covid-19 on breast cancer stage at discovery, and time to treatment in Cote d'Or, France.
Clémence Feron Agbo, Emerline Assogba, Aurélie Bertaut, Ariane Mamguem Kamga, Charles Coutant, Isabelle Desmoulins

Prev Med Rep· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort.
Thomas Grinda, Alison Antoine, William Jacot, Paul-Henri Cottu, Thibault de la Motte Rouge, Isabelle Desmoulins

Eur J Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anticipating changes in the HER2 status of breast tumours with disease progression-towards better treatment decisions in the new era of HER2-low breast cancers.
Anthony Bergeron, Aurélie Bertaut, Françoise Beltjens, Céline Charon-Barra, Alix Amet, Isabelle Desmoulins

Br J Cancer· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intracranial response of brain metastases in patients with HER2-amplified breast cancer treated with trastuzumab-deruxtecan after failure of tucatinib-based therapy.
Isabelle Desmoulins, Hélène Bellio, Nathalie Méjean, Caroline Truntzer, Sylvain Ladoire

Eur J Cancer· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials.
Elie Rassy, Thomas Filleron, Alessandro Viansone, Magali Lacroix-Triki, Sofia Rivera, Isabelle Desmoulins

Breast Cancer Res Treat· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study.
Samia Kada Mohammed, Oumar Billa, Sylvain Ladoire, Clementine Jankowski, Isabelle Desmoulins

Breast Cancer· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results.
Manon Réda, Anaïs Fouquier, Isabelle Desmoulins, Didier Mayeur, Courèche Kaderbhai

Breast· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort.
Laetitia Collet, Lauriane Eberst, Gauthier Ludovic, Marc Debled, Loana Hrab, Isabelle Desmoulins

Breast Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study.
Hélène François-Martin, Audrey Lardy-Cléaud, Barbara Pistilli, Christelle Levy, Véronique Diéras, Isabelle Desmoulins

Cancers (Basel)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer.
Loïck Galland, Nicolas Roussot, Isabelle Desmoulins, Didier Mayeur, Courèche Kaderbhai

Cancers (Basel)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognosis of local invasive relapses after carcinoma in situ of the breast: a retrospective study from a population-based registry.
Samia Kada Mohammed, Tienhan Sandrine Dabakuyo Yonli, Isabelle Desmoulins, Ariane Manguem Kamga, Clémentine Jankowski

Breast Cancer Res Treat· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes.
Marcela Carausu, Matthieu Carton, Véronique Diéras, Thierry Petit, Séverine Guiu, Isabelle Desmoulins

JAMA Netw Open· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.
Elise Ballot, Loïck Galland, Hugo Mananet, Romain Boidot, Laurent Arnould, Isabelle Desmoulins

Breast Cancer Res· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis